Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci Buys 11,500 Shares

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci purchased 11,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Celldex Therapeutics Stock Performance

Shares of CLDX traded up $1.17 during mid-day trading on Tuesday, hitting $27.38. The company’s stock had a trading volume of 112,923 shares, compared to its average volume of 869,602. The stock’s 50-day moving average is $33.29 and its two-hundred day moving average is $35.72. The firm has a market capitalization of $1.82 billion, a PE ratio of -10.20 and a beta of 1.60. Celldex Therapeutics, Inc. has a one year low of $24.43 and a one year high of $53.18.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Citigroup assumed coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, November 7th. Finally, The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Celldex Therapeutics during the second quarter worth $76,000. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares during the period. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics during the first quarter valued at $147,000. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.